Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

MRNA dominated the tape, swinging from $60.82 to $176.66 (+190.46%) and closing at $143.97 — 71.75% of its range — with realized volatility of 352.46% against 72.24% implied, a 20.56x vol surprise that stands out as the single largest mispricing in the dataset. EBS (+48.98%) and TEM (+47.84%) also posted outsized ranges, though only EBS held near its highs (82.49% of range); TEM closed at 40.96% and BNTX at just 20.91% despite a 32.84% range, indicating gains were surrendered late.

The decliners cluster tightly at the bottom of their ranges: AMGN (0.16%), LLY (1.09%), ANAB (1.60%), ABT (2.90%), DBVT (3.61%), ADMA (3.78%) and XLV (2.26%) all finished within a few percent of their lows — a broad, synchronized weakness rather than isolated damage. SYK's -19.34% period return alongside a 2.63x realized/implied ratio and ABT's 1.95x show implied vol underpricing moves in large-cap names. Conversely, ANAB (0.55x), ADMA (0.61x), CDXS (0.63x) and DBVT (0.75x) saw options markets overprice volatility that never materialized.

Broader Market Context

Differential behavior within the sector. The dispersion here is extreme for a single sector: roughly 233 percentage points separate MRNA (+190.46%) from KPTI (-42.06%). That spread is far wider than the sector benchmark's own move — XLV fell only 6.50% top-to-bottom and closed 2.26% off its low with 20.03% realized volatility, the calmest reading in the set. The pattern splits cleanly:

• Biotech/vaccine and small-cap names (MRNA, EBS, BNTX, TEM) delivered the upside, with realized vol between 59% and 352%.
• Large-cap pharma and devices (LLY -13.88%, AMGN -15.61%, ABT -13.51%, SYK -22.36%) were uniformly weak, and several closed essentially at their lows.
• Managed care was mixed-to-resilient: HUM (+13.05%), ELV (+9.86%) and CI held up, while UNH and CNC lagged — consistent with idiosyncratic differentiation rather than a uniform group trade.
• Micro-cap biotech (KPTI, CDXS, STIM, DBVT) sold off hard on triple-digit implied vols that still overstated realized moves.

Rotation vs. stock-specific moves. This does not look like a clean defensive rotation *into* healthcare — the sector proxy fell, and the mega-cap defensives led the decline. The more plausible reading is a rotation *out of* large-cap pharma/device ballast paired with aggressive, selective risk-taking in high-beta biotech. MRNA's 20.56x vol surprise is the signature of a single-name catalyst, not a macro repricing; the same applies to EBS, TEM and KPTI, whose moves were far too large and too divergent to share a common driver.

Plausible sector-relevant drivers. The behavior is consistent with several live themes, though none can be confirmed from this data alone:

• Ongoing drug-pricing and reimbursement policy uncertainty, which tends to weigh disproportionately on large-cap pharma and managed care margins.
• Clinical trial, FDA decision, or approval-cycle catalysts, which typically produce exactly this kind of binary, vol-crushing move in single biotech names.
• Rate and risk-appetite shifts, which matter more for long-duration, cash-burning small-cap biotech than for cash-generative incumbents.
• M&A speculation, a recurring source of asymmetric upside in mid- and small-cap healthcare when large-cap pipelines face patent pressure.

The recurring theme: implied volatility systematically underpriced large-cap moves (SYK 2.63x, AMGN 2.11x, ABT 1.95x) while overpricing the micro-caps — a positioning asymmetry worth noting.